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Abstract 
Review on Blastic Plasmacytoid Dendritic Cell 
Neoplasm (BPDCN), with data on clinics, and the 
genes involved. 
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Clinics and pathology 
Disease 
Phenotype/cell stem origin 
Blastic plasmacytoid dendritic cell neoplasm 
(BPDCN) is a rare and aggressive hematologic 
neoplasm. Despite its rarity, there is extensive 
historic and scientific literature. Since 1994, when 
this neoplasm was first described (Adachi et al., 
1994), BPDCN has been known with various names, 
including agranular CD4+ natural killer (NK) 
leukemia, CD4+/CD56+ hematodermic neoplasm, 
and blastic NK lymphoma (Facchetti et al., 2009; 
Pilichowska et al., 2007; Petrella et al., 2005; Assaf 
et al., 2007). In 2008, the WHO has placed this 
neoplasm in the category of acute myeloid leukemia 
(AML) and related precursor neoplasms (Facchetti et 
al., 2008; Swerdlow et al., 2008) following the 
realization that BPDCN results from the clonal 
proliferation of immature plasmacytoid dendritic 
cells (PDC) (Facchetti et al., 2008). In normal 
situations, the PDC are an essential part of the innate 
adaptive immunoresponse (Jegalian et al., 2009; 
Reizis et al., 2011). These cells respond to viral and 
bacterial infection by producing alpha-interferon. As 
such, they are also known also as alpha-interferon 
producing cells or plasmacytoid monocytes. 
Expansion of the normal PDCs can occur in 
autoimmune disorders, as well as Hodgkin 
lymphoma, and various carcinomas. Flow cytometry 
and immunohistochemistry studies have revealed 
that the neoplastic PDC of virtually all patients are 
typically found in the CD45dim blast gate region and 
are phenotypically defined by the co-expression of 
CD4, CD56, and CD123, absence of CD34, and lack 
of specific myeloid-, T-, B-, or NK-lineage markers 
(Pagano et al., 2013). Very rarely CD56 might not be 
expressed. In those cases, the expression of CD4, 
CD123, and TCL1 would be sufficient to suspect 
BPDCN (Herling et al., 2003). Approximately 50% 
of the cases might also express CD43, CD45RA, and 
CD68. Other markers observed less frequently 
include CD7, HLA-DR, TCL1, CD33, 
BDCA2/CD303, BDCA4/CD304, CLA, and MxA 
(Petrella et al., 2004; Pilichowska et al., 2007). 
Epidemiology 
BPDCN is quite rare; less than 100 cases have been 
reported so far. The disease does not have a 
geographic predilection as it has been observed in 
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various countries around the world (Tsagarakis et al., 
2010; Qayoom et al., 2015; Assaf et al., 2007). The 
exact incidence might be difficult to determine due 
to the various definitions of BPDCN as a leukemia 
or a skin lymphoma prior to the 2008 WHO inclusion 
of this neoplasm into the AML and related 
precursors neoplasms (Facchetti et al., 2008). Recent 
reports in the incidence, indicate that this neoplasm 
accounts for 0.4% of all hematologic neoplasms, 
0.7% of the primary cutaneous lymphomas, and less 
than 1% of all acute leukemias (Facchetti et al., 
2008; Riaz et al., 2014; Rossi et al., 2006; Pagano et 
al., 2013). BPDCN has been described in all age 
groups, but is most common in adults; the majority 
of patients are older adults and the median age at 
diagnosis is 65 years. Some patients are younger 
than 40 years old, and even children with this 
neoplasm have been reported. The male to female 
ratio is 3:1. 
Clinics 
The first symptom in most patients with BPDCN is 
the presence of multiple cutaneous lesions, often 
detected incidentally by dermatologists (Gera et al., 
2014). As such, histologic diagnosis is required to 
distinguish BPDCN from other primary skin lesions 
or other leukemias and lymphomas characterized by 
cutaneous involvement (Gera et al., 2014). At the 
same time, or soon after, involvement of bone 
marrow and/or peripheral blood occurs. This 
involvement is thought to occur in approximately 
90% of the cases. Lymph nodes might also be 
involved (approximately 50% of the cases). Overt 
leukemia is a common feature of BPDC during 
progression or relapse, often with a myelomonocytic 
phenotype, and is nearly always present in the 
terminal stage of the disease. However, a minority of 
patients (5-10% of cases) do not have cutaneous 
lesions, but present with a very aggressive 
(fulminant) leukemia (Wang et al., 2012; Rauh et al., 
2012; Qayoom et al., 2015). In addition to the 
typically sites of involvement, other unusual sites 
might be also affected. Paluri et al. (2015) reported a 
patient diagnosed with a BPDCN confined to the 
sinonasal region and central nervous system (CNS). 
Although CNS is not typically considered a common 
site of involvement for BPDCN, a recent study has 
reported a frequent CNS involvement in their group 
of patients suggesting that the CNS might be a safe 
reservoir of blast cells in patients with leukemic 
presentation, due to the fact that drugs are unable to 
cross the blood-brain barrier (Martin-Martin et al., 
2016). Regardless of the presentation, the overall 
prognosis for patients with BPDCN is unfavorable, 
with a median overall survival of approximately one 
year (Facchetti et al., 2008; Julia et al., 2013). In 
children, BPDCN is characterized by less frequent 
cutaneous involvement and a significant response to 
intensive acute lymphoblastic leukemia (ALL)-type 
chemotherapy, allowing patients to reach complete 
remission. The overall prognosis and long-term 
survival in pediatric patients is better than in adults. 
Some reports made the suggestion that childhood 
BPDCN might represent a different neoplasm than 
the one seen in adults (Jegalian et al., 2010; Rossi et 
al., 2006). 
 
Immunohistologic studies on lymph node sections show reactivity for CD56 and CD43 and lack reactivity for 
CD45 and TdT (original magnification ×375). Image available at Blastic plasmacytoid dendritic cell neoplasm. 
PathologyOutlines.com website. 
http://www.pathologyoutlines.com/topic/lymphomanonBblasticplasmacytoid.html. Accessed April 30th, 2017 
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Cytology 
Examination of BPDCN patients with skin 
presentation reveals that the neoplasm involves the 
entire dermis and may extend to the subcutis, but not 
the epidermis (Gera et al., 2014. When the bone 
marrow is affected, there is a variable degree of 
involvement with variable dysplasia. The lymph 
nodes show a diffuse interfollicular and medullary 
involvement. Microscopic examination of the skin 
biopsy typically shows a diffuse monotonous 
infiltrate of intermediate-sized blast cells with round 
to oval nuclei and nucleoli, and scant agranular 
cytoplasm that resemble myeloid blasts, but with NK 
cell lineage differentiation (Ferreira et al., 2016; Ru 
et al., 2014). Intracytoplasmic microvacuoles are 
present in the majority of cases (Ferreira et al., 
2016). The mitotic activity is variable. 
 
(A) Lymph node biopsy. Monomorphous infiltrate of medium-sized cells with scant cytoplasm, round nuclear 
contours, finely granular chromatin, and numerous mitotic figures (hematoxylin-eosin, original magnification 
×375); (B) Bone marrow core biopsy specimen. Hypercellular marrow with trilineage hematopoiesis and an 
interstitial infiltrate of immature blast-like cells (hematoxylin-eosin, original magnification ×375). (C) Peripheral 
blood smear after bone marrow transplantation. Immature blasts with high nuclear-to-cytoplasmic ratio, 
agranular cytoplasm, and round nuclear contours (Wright-Giemsa, original magnification ×500). Image available 
at Blastic plasmacytoid dendritic cell neoplasm. PathologyOutlines.com website. 
http://www.pathologyoutlines.com/topic/lymphomanonBblasticplasmacytoid.html. Accessed April 30th, 2017 
 
Prognosis 
BPDCNA is an aggressive neoplasm with a median 
survival of approximately 12 months and typically 
poor response to chemotherapy (Facchetti et al., 
2008; Julia et al., 2013). Patients with the leukemic 
form of the neoplasm have a shorter survival 
(approximately 8 months) (Riaz et al., 2014). Since 
skin presentation occurs in the majority of patients, 
the first therapeutic approach is targeted to treat the 
skin lesions. There is no specific induction therapy 
designed specifically to treat this neoplasm. Patients 
have been treated with existing therapies typically 
used for non-Hodgkin lymphoma, AML, and ALL 
(Falcone et al., 2016). Various AML and ALL 
therapeutic protocols have been used. The AML 
protocol consists of variable combinations of 
cytarabine, etoposide, idarubicin, anthracycline, 
fludarabine, and filgrastim, whereas the ALL 
protocol includes variable combinations of 
cyclophosphamide, vincristine, doxorubicin, 
dexamethasone, methotrexate, cytarabine, 
prednisone, asparaginase, and CHOP with and 
without etoposide (Pagano et al., 2013). 
Approximately 90% of patients seem to respond 
initially to these therapies, but the disease later recurs 
in the majority of patients (Bayerl et al., 2002). 
However, Voelkl et al. (2011) reported an elderly 
patient with BPDCN with AML presentation and 
skin lesions who achieved a 26 month long remission 
after treatment with dose intensive multiagent 
chemotherapy. Long lasting remissions might occur 
in pediatric patients with good response to acute 
leukemia chemotherapy and allogeneic stem cell 
transplantation (Paluri et al., 2015; Male et al., 
2010). Several studies have demonstrated that 
allogeneic stem cell transplantation following a 
reduced intensity conditioning (avoidance of high-
dose therapy) offers the best chance for long lasting 
remission, particularly when performed during the 
first complete remission, and suggests that this form 
of therapy should be pursued aggressively for all 
BPDCN patients (Dietrich et al. 2011; Roos-Weil et 
al., 2013; Aoki et al., 2015). There are also clinical 
trials presently being conducted that are showing 
promising results. One of these trials consists in the 
administration of a single cycle of therapy of SL-
401. This is a recombinant human interleukin 3a 
protein conjugated with truncated diphtheria a-toxin 
DT388-IL3, a potent inhibitor of protein synthesis 
(Stemline Therapeutics) (Frankel et al., 2014; 
Fitzgerald et al., 2014). The other clinical trial 
consists of a targeted therapy against CD56+ tumors. 
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The drug in in this case is lorvotuzumab mertansine, 
which has been used to targets other hematologic 




G-banded karyotype of a patient with BPDCN: 
44,XY,del(5)(q15q33),del(6)(q13q23),add(9)(p13),add(12)(p11.2),-13,-15, add(17)(p12). Hypodiploidy with 
deletions of 5q, 6q, 9p, 12p, and 17p is a common finding. Typically these karyotypes also show loss of 




An interesting fact about BPDCN is that the 
chromosome abnormalities are more similar to those 
that have been observed in high-grade 
myelodysplasia (MDS) and AML with MDS-related 
changes than those that have been described in 
lymphoma. Karyotypes are usually are complex like 
those that have also been described in therapy related 
MDS/AML, and are often hypodiploid. Recurrent 
deletions, some leading to loss of specific gene, have 
been identified by both conventional cytogenetics 
and array comparative genomic hybridization 
(aCGH) (Leroux et al., 2002; Oiso et al., 2012; 
Lucioni et al., 2011; Dijkman et al., 2007). The most 
common deletions are those involving 5q (72% of 
cases), 12p13.1-p13.2/ CDKN1B (64%), 13q13.1-
14.2/ RB1 (64%), 6q (50%), 15q (43%), 9p21.3/ 
CDKN2A/ CDKN2B (28%), and 7p12.2/ IKZF1. 
Among these, the biallelic loss of 9p21.3 suggests a 
more aggressive course. In addition, three cases of 
MLL rearrangement, two with t(11;19)(q23;p13.3) 
KMT2A/ MLLT1 and one with a 3-way 
t(4;9;11)(q12;p22;q23) have been reported in 3 
patients aged 8, 42, and 50 years old, respectively 
(Leung et al., 2006; Toya et al., 2012; Yang et al. 
2015). The involvement of MLL and the other 
recurrent chromosome abnormalities observed in 
BPDCN might pose a challenge for differentiating 
PBDCN from MDS, AML, or ALL since some of the 
abnormalities seen in PBDCN are common to these 
neoplasms. Therefore, authors urge careful 
evaluation of suspected cases of BPDCN and 
encourage the use of plasmacytoid dendritic cell 
markers to ensure that the blasts have no expression 
of myeloid or monocytic markers (particularly cases 
with MLL rearrangements), as well as perform 
extensive immunohistochemical and genetic 
analyses before definitively considering the 
diagnosis of BPDCN (Lee et al., 2016). In contrast, 
it is relatively easier to genetically differentiate 
BPDCN from NK neoplasms, since BPDCN does 
not have rearrangements of heavy chain, light chain, 
or T-cell receptor genes. 
Genes involved and 
proteins 
In addition to the loss of tumor suppressor genes due 
to the various chromosome deletions mentioned in 
the cytogenetic section (i.e., CDKN1B, RB1, 
CDKN2A/CDKN2B, and IKZF1), several mutations 




Atlas Genet Cytogenet Oncol Haematol. 2018; 22(6) 250 
 
involving oncogenes have been described. The most 
common are TET2 at 4q24 (57%), ZRSR2 at Xp22.2 
(57%), TP53 at 17p13.2 (14%), and ASXL1 at 
20q11.2 (Jardin et al., 2011; Alayed et al., 2013). 
Exome sequencing has also revealed mutations of 
other less common genes such as IKZF3 at 17q12, 
HOXB9at 17q21.3, UBE2G2 at 21q22.3 and ZEB2 
at 2q22.3 (Menezes et al., 2014). Furthermore, some 
patients were found to have a FLT3-ITD mutation 
(Pagano et al. 2013). 
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